Thank you to our speakers, sponsors, and delegates who joined us in Boston for the summit! If you are interested in the 2026 event, please get in touch at info@hansonwade.com.
Translating Optimized TIL Selection, Engineering, & Manufacturing into Potent Scalable Solid Tumor Treatments Beyond Melanoma
One year on from the first approved TIL Therapy in the US, and with Canada and EMA expected to make approval decisions in the coming months, this is a pivotal time for drug developers looking to address treatment-resistant solid tumors.
Returning for its 7th year, the TIL Therapies Summit remained the go-to forum for this close-knit community, created with the mission to transform end-to-end TIL development and deliver best-in-class therapies to treat solid tumor indications with significant unmet needs.
With more patients being treated than ever, this summit united a global collective of biopharma, academic thought leaders, clinicians, and patients as they shared their cutting-edge research into engineered TIL, easier manufacturing, and lived experiences with TIL Therapies.
The 2025 World-Class Speaker Faculty Included
Attending Companies Included